Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 13/20 | 0.40 |
| ▸ | HTR2C | P28335 | 13/20 | 0.40 |
| ▸ | HTR2A | P28223 | 12/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30040395 | 0.79 | PARP1 (0.49) | PARP1HTR2BHTR2CHTR2AHTR3E | |
| SCHEMBL21008766 | 0.79 | PARP1 (0.49) | PARP1HTR2BHTR2CHTR2AHTR3E | |
| SCHEMBL30212434 | 0.79 | PARP1 (0.49) | PARP1HTR2BHTR2CHTR2AHTR3E | |
| SCHEMBL16382727 | 0.79 | PARP1 (0.49) | PARP1HTR2BHTR2CHTR2AHTR3E | |
| SCHEMBL30763946 | 0.79 | CRBN (0.53) | PARP1HTR2BHTR2CHTR2AHTR3E | |
| SCHEMBL23880784 | 0.78 | PARP1 (0.48) | PARP1HTR2BHTR2CHTR2AHTR3E | |
| Hydrochloric Acid SCHEMBL16337337 | 0.78 | PARP1 (0.48) | PARP1HTR2BHTR2CHTR2AHTR3E | |
| Hydrochloric Acid SCHEMBL16334754 | 0.78 | PARP1 (0.48) | PARP1HTR2BHTR2CHTR2AHTR3E | |
| SCHEMBL21614132 | 0.78 | PARP1 (0.59) | PARP1HTR2BHTR2CHTR2AHTR3E | |
| SCHEMBL30366187 | 0.78 | PARP1 (0.59) | PARP1HTR2BHTR2CHTR2AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | PARP1 3520/4885HTR2B 244/4885HTR2C 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.